Comprehensive Metabolic Panel Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Comprehensive Metabolic Panel Market Report - Table of Contents

1. INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Awareness Regarding Early Diagnosis and Treatment of Diseases
  • 4.2.2 Increasing Prevalence of Chronic Diseases
• 4.3 Market Restraints
  • 4.3.1 Lack of Skilled Professionals
  • 4.3.2 Stringent Regulatory Policies
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

• 5.1 By Test Type
  • 5.1.1 Proteins
  • 5.1.2 Kidney Tests
  • 5.1.3 Electrolytes
  • 5.1.4 Liver Function Tests
  • 5.1.5 Glucose
  • 5.1.6 Other Test Types
• 5.2 By Disease
  • 5.2.1 Kidney Diseases
  • 5.2.2 Diabetes
  • 5.2.3 Liver Diseases
  • 5.2.4 Other Diseases
• 5.3 By End User
  • 5.3.1 Point-of-care Centers
  • 5.3.2 Laboratories
• 5.4 Geography
  • 5.4.1 North America
  • 5.4.1.1 United States (By Test Type, Disease, and End User)
  • 5.4.1.2 Canada (By Test Type, Disease, and End User)
  • 5.4.1.3 Mexico (By Test Type, Disease, and End User)
  • 5.4.2 Europe
  • 5.4.2.1 Germany (By Test Type, Disease, and End User)
  • 5.4.2.2 United Kingdom (By Test Type, Disease, and End User)
  • 5.4.2.3 France (By Test Type, Disease, and End User)
  • 5.4.2.4 Italy (By Test Type, Disease, and End User)
  • 5.4.2.5 Spain (By Test Type, Disease, and End User)
  • 5.4.2.6 Rest of Europe (By Test Type, Disease, and End User)
  • 5.4.3 Asia-Pacific
  • 5.4.3.1 China (By Test Type, Disease, and End User)
  • 5.4.3.2 Japan (By Test Type, Disease, and End User)
  • 5.4.3.3 India (By Test Type, Disease, and End User)
  • 5.4.3.4 Australia (By Test Type, Disease, and End User)
  • 5.4.3.5 South Korea (By Test Type, Disease, and End User)
  • 5.4.3.6 Rest of Asia-Pacific (By Test Type, Disease, and End User)
  • 5.4.4 Middle-East and Africa
  • 5.4.4.1 GCC (By Test Type, Disease, and End User)
  • 5.4.4.2 South Africa (By Test Type, Disease, and End User)
  • 5.4.4.3 Rest of Middle-East and Africa (By Test Type, Disease, and End User)
  • 5.4.5 South America
  • 5.4.5.1 Brazil (By Test Type, Disease, and End User)
  • 5.4.5.2 Argentina (By Test Type, Disease, and End User)
  • 5.4.5.3 Rest of South America (By Test Type, Disease, and End User)

6. COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Quest Diagnostics
  • 6.1.2 Laboratory Corporation of America Holdings
  • 6.1.3 Sonic Healthcare Limited
  • 6.1.4 SYNLAB International GmbH
  • 6.1.5 Charles River Laboratories Inc.
  • 6.1.6 ARUP Laboratories
  • 6.1.7 NeoGenomics Laboratories Inc.
  • 6.1.8 Genoptix Inc.
  • 6.1.9 CENTOGENE AG
  • 6.1.10 UNIPATH
  • 6.1.11 Abbott Laboratories
  • 6.1.12 Abaxis Inc. (Zoetis)
  • 6.1.13 TCG Corp.
  • 6.1.14 Scion Lab Services LLC
• *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS